Form 4: Agenus CEO Opts for Stock Compensation, Boosting Alignment

Agenus Inc.'s Chairman and CEO, Garo H. Armen, received 4,316 shares of common stock as salary, aligning executive interests with shareholders.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 4,316 shares of common stock.
• The shares were issued on December 12, 2025, as payment for his salary, in lieu of cash, at his request and with Compensation Committee approval.
• The transaction price per share was $3.79, which was the closing price of Agenus common stock on December 12, 2025.
• Following this transaction, Dr. Armen directly beneficially owns 302,401 shares of common stock.
• Indirect beneficial ownership includes 31,298 shares held in IRA accounts and 28,950 shares held by the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The CEO's decision to take salary in stock is generally viewed positively as it enhances alignment with shareholder interests, indicating confidence in the company's future performance.

Positives

• The CEO's decision to receive salary in stock rather than cash demonstrates a strong alignment of management's interests with those of shareholders.
• The shares issued are fully vested on the date of issuance, indicating immediate ownership and commitment.

Future Outlook

This filing does not contain explicit forward-looking statements or guidance beyond the reported transaction.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

Executive compensation in the form of equity is a common practice across industries, particularly in biotechnology, to align the interests of management with long-term shareholder value creation. This move by Agenus's CEO is consistent with such industry trends.

Comparison to Industry Standards

• The practice of executives receiving stock in lieu of cash salary is a well-established mechanism for aligning management incentives with shareholder interests, often seen in growth-oriented companies like those in the biotech sector.
• Many companies, including peers in the pharmaceutical and biotechnology space, utilize equity compensation plans to retain key talent and motivate performance tied to stock price appreciation.

Related Party Transactions

• The transaction involves the payment of salary to Garo H. Armen, the Chairman and CEO, in the form of company stock, which is a related party transaction.

Stakeholder Impact

• Shareholders may view the CEO's decision to accept stock as salary as a positive signal, indicating management's commitment and belief in the company's long-term prospects.
• Employees may see this as a sign of leadership's confidence in the company's future.

Key Dates

Keywords

Agenus Inc., AGEN, Garo H. Armen, Form 4, insider transaction, stock compensation, CEO salary, equity incentive, beneficial ownership